Historically, warfarin has been commonly used for both the management of prophylaxis and treatment in venous thromboembolism (VTE) and nonvalvular atrial fibrillation (NVAF) stroke prophylaxis. The risks associated with warfarin are well-established and the role of various agents for reversal is well understood. However, newer agents, referred to as direct oral anticoagulants (DOACs), have been approved for these same indications. Based on the current robust medical evidence, recent guideline updates have placed a preference on the use of DOACs over warfarin for most patient populations in need of oral anticoagulation. However, methods to manage bleeding associated with each DOACs , and the efficacy and safety of new reversal agents is not well understood.

The desired outcome of this presentation is to ensure our clinicians have the necessary information and resources needed to appropriately treat bleeding in patients using a DOAC for anticoagulation. Attendees will have an increased understanding of each reversal agent for each DOAC, including safety and efficacy, and awareness of its appropriate place in therapy. This presentation will facilitate the continued improvement of safety and quality care in the patient population requiring oral anticoagulants.